<DOC>
	<DOCNO>NCT01189643</DOCNO>
	<brief_summary>This study add irinotecan , temozolomide bevacizumab chemotherapy regimen currently use treat Desmoplastic small round cell tumor ( DSRCT ) . The investigator study find effect , good and/or bad , combination irinotecan , temozolomide bevacizumab patient DSRCT cancer .</brief_summary>
	<brief_title>Irinotecan , Temozolomide Bevacizumab Combination With Existing High Dose Alkylator Based Chemotherapy Treatment Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor</brief_title>
	<detailed_description />
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<criteria>Age great equal 1 year , less 30 year Newly diagnose , previously untreated patient histologically molecularly confirm DSRCT Adequate hematologic function : Absolute neutrophil count ≥ 1,000/mm3 Platelet count ≥ 100,000/mytm3 Adequate renal function : Normal creatinine age OR Creatinine clearance radioisotope GFR ≥ 70ml/min/1.73 m2 Adequate hepatic function : Total bilirubin ≤ 1.5 x ULN age AST ≤ 2.5 x ULN age [ absence hepatic involvement tumor ] Normal cardiac function Shortening fraction great equal 28 % echocardiogram OR Left ventricular ejection fraction ( LVEF ) great equal 50 % technetium99m pertechnetate radionuclide cineangiography ( MUGA ) echocardiogram Hypertension must well control stable dos medication least two week prior enrollment . Patients must consent indwell central venous catheter . Sexually active patient reproductive potential must willing use effective method contraception . Prior chemotherapy radiotherapy Pregnant breastfeeding female Patients document chronic nonhealing wound , ulcer bone fracture . Incomplete heal previous oncologic major surgery . Surgical procedure : Patients undergo major surgery ( include open biopsy , thoracotomy , organ resection , exploratory laparotomy , arteriovenous graft ) &lt; 28 day prior enrollment bevacizumab dose delay outline section 9.1 Patients must least 48 hour placement central catheter receive first dose bevacizumab Minor surgical procedure ( needle/laparoscopic core biopsy ) limit purpose tissue retrieval allow . Patients receive first plan dose bevacizumab wound heal 7 day elapse since procedure . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . Thrombosis : Patients must deep venous arterial thrombosis ( noncentral venous catheter relate ) within last three month prior study entry . Patients cerebrovascular accident transient ischemic attack within 6 month therapy exclude History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study entry . CNS status : Patients must know CNS metastasis leptomeningeal disease . Screening brain imaging require asymptomatic patient . Proteinuria : Urine protein : creatinine ratio great equal 1.0 Uncontrolled hypertension ( define SBP and/or DBP &gt; 95th percentile age ) Prior history hypertensive crisis hypertensive encephalopathy NYHA Grade II great congestive heart failure History myocardial infarction unstable angina within 12 month prior Day 1 History stroke transient ischemic attack Significant vascular ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 History hemoptysis ( great equal 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 Known hypersensitivity component bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>BEVACIZUMAB ( AVASTIN )</keyword>
	<keyword>IRINOTECAN ( CPT-11 ) CAMPTOSAR</keyword>
	<keyword>TEMOZOLOMIDE</keyword>
	<keyword>DSRCT</keyword>
	<keyword>10-091</keyword>
</DOC>